Sam Brusco, Associate Editor06.08.22
Medical diagnostic supplies and equipment maker StatLab Medical Products has acquired CellPath, a UK-based provider of histology and cytology products and services. The transaction adds new manufacturing capabilities and UK customer base.
StatLab now expands its European reach with key injection molding capabilities as well as proprietary products including the CellNass archiving service. CellPath will continue to operate in the same locations and under the existing leadership structure.
"We have long respected CellPath for their well-earned reputation of delivering innovative products that solve problems for labs, and are proud to welcome them to the StatLab family of brands,” Mike Karsonovich, CEO of StatLab told the press. “Now paired with the strategic acquisition of UK-based equipment manufacturer Pyramid Innovation in 2021, CellPath’s established European market position and complementary portfolio will empower meaningful international growth in the histology sector.”
Philip Webber, CellPath Joint Managing Director along with his brother Paul, added, “StatLab is an excellent fit for us; their US market access and business infrastructure will help jointly expand customer access to products and services as a global market leader. We also appreciate their leadership commitment to ensure we maintain the high levels of service and quality that our family’s business is known for as we partner as one organization.”
StatLab now expands its European reach with key injection molding capabilities as well as proprietary products including the CellNass archiving service. CellPath will continue to operate in the same locations and under the existing leadership structure.
"We have long respected CellPath for their well-earned reputation of delivering innovative products that solve problems for labs, and are proud to welcome them to the StatLab family of brands,” Mike Karsonovich, CEO of StatLab told the press. “Now paired with the strategic acquisition of UK-based equipment manufacturer Pyramid Innovation in 2021, CellPath’s established European market position and complementary portfolio will empower meaningful international growth in the histology sector.”
Philip Webber, CellPath Joint Managing Director along with his brother Paul, added, “StatLab is an excellent fit for us; their US market access and business infrastructure will help jointly expand customer access to products and services as a global market leader. We also appreciate their leadership commitment to ensure we maintain the high levels of service and quality that our family’s business is known for as we partner as one organization.”